



Fighting blood clots through education

Anticoagulation Comparison Chart: A Quick Guide for Prescribers

For more information, please visit thrombosis.org

This chart is for general informational purposes and notes FDA-approved indications for oral anticoagulants only. The information presented here does not capture all clinical scenarios in which anticoagulation may be used. For specific questions, please contact your pharmacy team.

BRAND	Jantoven® Warfarin* <small>*Coumadin® was discontinued in April 2020.</small>	Eliquis® (apixaban) tablets	Xarelto® rivaroxaban	Pradaxa® Dabigatran	Savaysa® (edoxaban) tablets 60mg/30mg
GENERIC	Yes	No	No	Yes	No
Indications Approved by the United States Food and Drug Administration (FDA)					
Stroke Prevention in Atrial Fibrillation (AF)					
AF without mechanical valves or mitral valve stenosis	✓	✓	✓	✓	✓
AF with mechanical valves or mitral valve stenosis	✓	✗	✗	✗	✗
Venous Thromboembolism (VTE)					
Treatment of VTE	✓	✓	✓	✓	✓
Secondary prevention in patients already treated for VTE	●	✓	✓	✓	✗
Prophylaxis after hip replacement surgery	●	✓	✓	✓	✗
Prophylaxis after knee replacement surgery	●	✓	✓	✗	✗
Prophylaxis in the hospital and after discharge in adults with acute medical illness	✗	✗	✓	✗	✗
Prophylaxis of major cardiovascular events in patients with CAD and/or PAD - and in combination with aspirin	✗	✗	✓	✗	✗

Boxes marked with a ● indicate well-established uses of warfarin that do not appear in the drug's package insert. Warfarin is also commonly used in antiphospholipid syndrome (APS). Please consult your pharmacy team for specific questions about warfarin use.

Acute medical illness: Conditions such as pneumonia, stroke, heart failure, infection, or inflammatory disease

CAD: Coronary artery disease








Major cardiovascular (CV) events: CV death, heart attack, and stroke

PAD: Peripheral artery disease

Anticoagulation Comparison Chart: A Quick Guide for Prescribers

This chart is for informational purposes only.

Please visit thrombosis.org for a patient-friendly version of this chart that you can distribute in your clinic or practice.

BRAND	Jantoven® Warfarin* <small>*Coumadin® was discontinued in April 2020.</small>	<i>Eliquis.</i> (apixaban) tablets Apixaban	 rivaroxaban Rivaroxaban	<i>Pradaxa</i> Dabigatran	 (edoxaban) tablets 60mg/30mg Edoxaban
DRUG IMAGE AND AVAILABLE DOSAGES (The front and back of each tablet is shown in these pictures.)	<p>Tablet</p>  <p>Colors and shapes vary by dose</p>	<p>Tablet</p>  <p>2.5 mg 5 mg</p>	<p>Tablet</p>  <p>2.5 mg 10 mg 15 mg 20 mg</p>	<p>Capsule</p>  <p>75 mg 110 mg 150 mg</p>	<p>Tablet</p>  <p>15 mg 30 mg 60 mg</p>
ONSET	Days	Hours	Hours	Hours	Hours
RENAL DOSE ADJUSTMENT	No	Yes	Yes	Yes	Yes
FOOD EFFECTS	Yes Vitamin K interactions	No	Yes Must take 15-mg and 20-mg doses with food	No	No
DRUG INTERACTIONS	Many	Few	Few	Few	Few
ROUTINE DRUG MONITORING	Yes	Not Needed Complete blood count and kidney/liver function tests recommended annually (more frequently in some patients)			
REVERSAL AGENTS If FDA-approved agents aren't available, 4-factor prothrombin complex concentrate (4F-PCC; brand name KCentra®) is an alternative for all agents.	Yes 4F-PCC Vitamin K, fresh frozen plasma	Yes Andexxa® (andexanet alfa)	Yes Andexxa® (andexanet alfa)	Yes Praxbind® (idarucizumab)	Not Yet No FDA-approved reversal agents currently